34th week of 2018 patent applcation highlights part 9 |
Patent application number | Title | Published |
20180235941 | PEDIATRIC ORAL SUSPENSION FORMULATIONS OF AMOXICILLIN AND CLAVULANATE POTASSIUM AND METHODS FOR USING SAME - The invention is directed to a pediatric oral suspension composition containing amoxicillin and clavulanate potassium where the clavulanate potassium is present in an amount equal to or less than about 21.5 mg/5 mL, and a method of treating bacterial infections by providing between about one to about fourteen dosage days of the composition. Also disclosed are methods of treating a patient comprising administering amoxicillin and clavulanate potassium to the patient in dosages of at least about 80 mg/kg/day of the amoxicillin and from about 1.66 mg/kg/day to about 2.84 mg/kg/day of the clavulanate potassium. The methods are useful for treating pediatric otitis media, treating a drug resistant bacterial infection, or treating beta-lactamase producing | 2018-08-23 |
20180235942 | METHODS OF SEDATION AND PARENTERAL FORMULATION FOR USE DURING CRITICAL CARE TREATMENT - Methods of sedating a patient undergoing critical care treatment using intravenous gaboxadol or a pharmaceutically acceptable salt thereof are provided. Parenteral formulations for critical care sedation using intravenous gaboxadol or a pharmaceutically acceptable salt thereof are provided. The parenteral formulations are particularly well suited for use in critical care sedation. | 2018-08-23 |
20180235943 | COMBINATION THERAPIES FOR TREATMENT OF SPINAL MUSCULAR ATROPHY - Disclosed herein are compositions and methods for treatment of spinal muscular atrophy (SMA). In certain embodiments, compounds are provided that increase full-length survival of motor neuron (SMN) protein production by an SMN2 gene. | 2018-08-23 |
20180235944 | RIFAXIMIN - Amorphous rifaximin, methods of making it, and pharmaceutical compositions containing it. Also described are methods of converting amorphous rifaximin to crystalline rifaximin and vice versa. | 2018-08-23 |
20180235945 | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF - Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure: | 2018-08-23 |
20180235946 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRESBYOPIA - The invention provides compositions and methods for the treatment of presbyopia. The compositions preferably comprise aceclidine, an alpha-adrenergic agonist, a cryoprotectant and a non-ionic surfactant. The compositions optionally contain a viscosity enhancer. | 2018-08-23 |
20180235947 | Liquid Pharmaceutical Composition - The present invention provides a physically and chemically stable pharmaceutical liquid composition including sodium picosulfate, magnesium oxide, citric acid and malic acid and methods of making and using such a composition. | 2018-08-23 |
20180235948 | (S,E)-3-(6-AMINOPYRIDIN-3-YL)-N-((5-(4-(3-FLUORO-3-METHYLPYRROLIDINE-1-CAR- BONYL)PHENYL)-7-(4-FLUOROPHENYL)BENZOFURAN-2-YL)METHYL)ACRYLAMIDE FOR THE TREATMENT OF CANCER - The invention generally relates to substituted benzofuranyl compounds and, more particularly, to a compound represented by Structural Formula 1a: (I) or a pharmaceutically acceptable salt thereof. The invention also includes the synthesis and use of the compound of Structural Formula 1a, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment of diseases or disorder selected from cancer (e.g., lymphoma, such as mantle cell lymphoma), a neurodegenerative disease, an inflammatory diseases or an immune system disease (e.g., a T-Cell mediated autoimmune disease) in a subject in need thereof. The method comprises administering to a subject in need thereof a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, or a composition comprising a compound of the invention, or a pharmaceutically acceptable salt thereof. | 2018-08-23 |
20180235949 | Substituted 1-Arylalkyl-4-Acylaminopiperidine Compounds and Methods of Producing and Using the Same - The present invention provides using a substituted 1-arylalkyl-4-acylaminopiperidine compound of Formula I: | 2018-08-23 |
20180235950 | DEUTERATED ANALOGS OF PRIDOPIDINE USEFUL AS DOPAMINERGIC STABILIZERS - The present invention provides novel deuterated analogs of Pridopidine, i.e. 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine. Pridopidine is a drug substance currently in clinical development for the treatment of Huntington's disease. | 2018-08-23 |
20180235951 | USE OF CERANIB-2 IN THE TREATMENT OF LUNG CANCER AND BREAST CANCER - The present invention relates to the use of ceranib-2 molecule in the treatment of lung cancer and breast cancer. At the same time, the present invention also describes the in vitro studies made by the inventors in this direction. | 2018-08-23 |
20180235952 | METHODS OF TREATING CANCER WITH FARNESYLTRANSFERASE INHIBITORS - The present invention relates to the field of cancer therapy. Specifically, provided are methods of treating cancer, for example, peripheral T-cell lymphoma (“PTCL”), with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on gene expression characteristics. | 2018-08-23 |
20180235953 | METHODS AND USES OF QUINOLINE DERIVATIVES IN THE TREATMENT OF SOFT TISSUE SARCOMAS AND PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF SAME - The present invention addresses methods and uses of quinoline derivatives in the treatment of tumours and pharmaceutical compositions for treatment of same. Specifically, the present invention involves a method and applications for the use of the quinoline derivative 1-[[[4-(4-fluoro-2-methyl-H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropylamine in the treatment of soft tissue sarcomas and pharmaceutical compositions for treatment of same. | 2018-08-23 |
20180235954 | LIPOSOMES USEFUL FOR DRUG DELIVERY - The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention. | 2018-08-23 |
20180235955 | ACETATE SALT OF BUPRENORPHINE AND METHODS FOR PREPARING BUPRENORPHINE - The present disclosure provides acetate salts of buprenorphine, and its anhydrates, solvates, hydrates, and crystalline forms thereof, where the acetate salts of buprenorphine are essentially free of impurities. The disclosure further provides method of preparing the acetate salts, buprenorphine free base prepared from the acetate salts, other salts prepared from the free base, and pharmaceutical compositions thereof essentially free of impurities. | 2018-08-23 |
20180235956 | TREATING PULMONARY CONDITIONS BY SELECTIVELY REMOVING SENESCENT CELLS FROM THE LUNG USING AN INTERMITTENT DOSING REGIMEN - Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders. | 2018-08-23 |
20180235957 | Treatment of Ophthalmic Conditions by Selectively Removing Senescent Cells from the Eye - Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders. | 2018-08-23 |
20180235958 | PANCREATITIS TREATMENT - Compositions and methods related to the amelioration of pancreatitis through the pharmaceutical manipulation of calcium signaling are disclosed. Such compositions and methods may be used to ameliorate symptoms of acute or chronic pancreatitis or to reduce the chance or severity of pancreatitis in an individual at risk of the condition. In other embodiments, disclosed herein are compositions and methods related to the amelioration of viral diseases through the pharmaceutical manipulation of calcium signaling. In further embodiments, disclosed herein are compositions and methods related to the amelioration of Th17-induced diseases through the pharmaceutical manipulation of calcium signaling. | 2018-08-23 |
20180235959 | USE OF CRAC CHANNEL INHIBITORS FOR THE TREATMENT OF STROKE AND TRAUMATIC BRAIN INJURY - Described herein are methods of treatment of stroke and traumatic brain injury comprising administration of a CRAC channel inhibitor. | 2018-08-23 |
20180235960 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS - Provided herein are methods for treating or preventing a solid tumor, non-Hodgkin lymphoma or multiple myeloma in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a solid tumor, non-Hodgkin lymphoma or multiple myeloma. | 2018-08-23 |
20180235961 | COMPOSITIONS AND METHODS FOR CANCER EXPRESSING PDE3A OR SLFN12 - The present invention features improved methods of identifying patients having cancer (e.g., melanoma, adenocarcinoma, lung, cervical, liver or breast cancer) using biomarkers (e.g., PDE3A, SLFN12) that correlate with drug sensitivity and consequently treating a stratified patient population with an agent of the invention (e.g., DNMDP, zardaverine, and anagrelide). | 2018-08-23 |
20180235962 | ACOUSTIC MIXING FOR AUTO GRANULATION - A process for acoustically mixing a bulk drug substance involves the application of acoustic energy to drive an accelerative force in a mixing vessel containing the drug substance. The drug substance may be, for example, Elagolix. | 2018-08-23 |
20180235963 | METHODS OF ADMINISTERING ELAGOLIX - The present disclosure relates to the use of GnRH receptor antagonists used in the treatment of endometriosis or uterine fibroids. In particular, the present disclosure describes a method of treating endometriosis or uterine fibroids, where the method involves the administration of elagolix, and where the method may further involve the co-administration of rifampin or ketoconazole. | 2018-08-23 |
20180235964 | CXCR-2 INHIBITORS FOR TREATING CRYSTAL ARTHROPATHY DISORDERS - N-(2-((2,3-difluorobenzyl)thio)-6-(((2R,3S)-3,4-dihydroxybutan-2-yl)oxy)pyrimidin-4-yl)azetidine-1-sulfonamide (compound 3) and N-(6-(((2R,3S)-3,4-dihydroxy butan-2-yl)oxy)-2-((4-fluoro benzyl)thio)pyrimidin-4-yl)-3-methyl-azetidine-1-sulfonamide (compound 4) are known chemokine modulators and are therefore useful in the treatment of diseases/conditions in which modulation of chemokine receptor activity is beneficial. In particular, provided herein are compositions and methods for the treatment and prevention of gout. | 2018-08-23 |
20180235965 | CRYSTAL FORM OF OREXIN RECEPTOR ANTAGONIST COMPOUND, AND PREPARATION METHOD AND APPLICATION THEREOF - Disclosed are a preparation method of an orexin receptor antagonist compound 5-3, Crystalline forms I-IV of an orexin receptor antagonist compound 5-3 are provided. Also provided are processes of the preparing the orexin receptor antagonist compound 5-3 and its crystalline forms, as well as methods of using the crystalline forms I-IV for treating an orexin-related disease. | 2018-08-23 |
20180235966 | PHARMACEUTICAL COMPOSITION OF ALOGLIPTIN AND METFORMIN - Present invention relates to a stable pharmaceutical composition comprising intimate mixture of alogliptin and metformin, and suitable pharmaceutically acceptable excipient/s; wherein metformin is present in about 3.3 parts or more parts by weight relative to 100 parts by weight of the total weight of part comprising alogliptin. Invention also encompasses various processes of preparing said pharmaceutical composition and its use in improving glycemic control in adults with type 2 diabetes mellitus. | 2018-08-23 |
20180235967 | PHARMACEUTICAL COMPOSITIONS COMPRISING AFATINIB - The present invention relates to a tablet comprising Afatinib or a pharmaceutically acceptable salt thereof, wherein the tablet is obtained by direct compression. The present invention further relates to a process for manufacturing a tablet of the invention as well as the use of the tablet of the invention. | 2018-08-23 |
20180235968 | EGFR MUTATIONS - The present invention relates to mutations in Epidermal Growth Factor Receptor (EGFR) and methods of detecting such mutations as well as prognostic methods method for identifying a tumors that are susceptible to anticancer therapy such as chemotherapy and/or kinase inhibitor treatment. The methods involve determining the presence of a mutated EGFR gene or mutated EGFR protein in a tumor sample whereby the presence of a mutated EGFR gene or protein indicates the tumor is susceptible to treatment. | 2018-08-23 |
20180235969 | LIQUID PHARMACEUTICAL COMPOSITION COMPRISING PEMETREXED - The present invention relates to a liquid pharmaceutical composition suitable for parenteral administration comprising: a) pemetrexed diacid; b) at least one organic amine; c) at least one antioxidant; d) 10-200 mg/ml of propylene glycol; and e) one or more parenteral solvents, wherein the preparation thereof is conducted in an atmosphere of inert gas and wherein the organic amine(s) is present in an amount sufficient to reach a pH of the composition in the range from 8.3 to 9.1 The invention further relates to the use of said liquid pharmaceutical composition as medicament in the treatment of malignant pleural mesothelioma and non-small cell lung cancer. | 2018-08-23 |
20180235970 | COMPOSITIONS AND METHODS FOR INCREASING ENERGY METABOLISM - Compositions and methods useful for inducing an increase in fatty acid oxidation or mitochondrial biogenesis, reducing weight gain, inducing weight loss, or increasing Sirt1, Sirt3, or AMPK activity are provided herein. Such compositions comprise a combination of a PDE 5 inhibitor, such as sildenafil or icariin, and resveratrol, and a branched amino acid such as leucine, or its metabolite. | 2018-08-23 |
20180235971 | MGLU2/3 ANTAGONISTS FOR THE TREATMENT OF INTELLECTUAL DISABILITIES - The invention relates to compounds which are mGlu2/3 negative allosteric modulators for use in the treatment of intellectual disabilities. In another aspect, the invention relates to a pharmaceutical composition for use in the treatment of intellectual disabilities comprising a compound according to the invention and a pharmaceutically acceptable carrier. | 2018-08-23 |
20180235972 | NOVEL FORMULATION AND TREATMENT METHODS - The invention relates to pharmaceutical compositions comprising 6-thioguanidine (6-TG) wherein the composition is formulated for release of 6-TG in the distal intestine. Methods for treating a disease or condition of the distal ileum that responds to 6-TG wherein the 6-TG is released in the distal intestine are also disclosed. | 2018-08-23 |
20180235973 | LIQUID FORMULATIONS OF FOSAPREPITANT - The present invention relates to liquid formulations of Fosaprepitant intended for parenteral administration. Further the invention also describes process for preparing such formulations. | 2018-08-23 |
20180235974 | COMPOUNDS COMPRISING TRICYCLIC HETEROCYCLIC COMPOUNDS - The invention relates to a pharmaceutical composition comprising a compound of formula I or a pharmaceutically acceptable salt thereof, and at least one pharmaceutical excipient selected from the group consisting of fillers, binders, disintegrants, glidants and lubricants, wherein the compound according to formula I is represented by: | 2018-08-23 |
20180235975 | METHOD FOR TREATING CANCER - The present disclosure relates to pharmaceutical compositions comprising inhibitor(s) of human histone methyltransferase EZH2, and methods of cancer therapy using the EZH2 inhibitor(s). | 2018-08-23 |
20180235976 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS - The present invention is related to pyrazolo pyridine derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase). | 2018-08-23 |
20180235977 | Treatment for Microbial borne illness - A method and a pharmaceutical composition for treating | 2018-08-23 |
20180235978 | METHOD FOR USE OF HOMOPIPERAZINIUM COMPOUNDS IN THE TREATMENT OF CANCER - A method for treating cancer including administering to a patient in need thereof an effective amount of a compound having the formula: | 2018-08-23 |
20180235979 | DOSAGE FORMS CONTAINING FLUTICASONE PROPIONATE FOR THE TREATMENT OF INFLAMMATORY CONDITIONS OF THE ESOPHAGUS - The present invention describes novel and improved dosage forms containing fluticasone propionate for the treatment of conditions associated with inflammation of the esophagus. | 2018-08-23 |
20180235980 | PHARMACEUTICAL FORMULATION - Disclosed are aqueous pharmaceutical compositions which provide sustained released delivery of corticosteroid compounds. The pharmaceutical composition comprises an insoluble corticosteroid; a soluble corticosteroid; and at least one viscosity enhancing agent. Also provided are methods for using the pharmaceutical compositions in an epidural injection, intra-articular injection, intra-lesional injection, or an intra-ocular injection. | 2018-08-23 |
20180235981 | C17-HETEROARYL DERIVATIVES OF OLEANOLIC ACID AND METHODS OF USE THEREOF - Disclosed herein are novel C17-heteroaryl derivatives of oleanolic acid, including those of the formula: | 2018-08-23 |
20180235982 | Treatment for Spirochete borne illness - A method and pharmaceutical composition for treating Spirochete phylum borne illnesses administered to a patient in need of such treatment at least one of tinidazole concentration between 10 to 10,000 mg dissolving bacterial biofilm or other nitroimidazole class drugs in combination with minocycline concentration of approximately 5 to 600 mg killing a bacterial infection co-administered with one of the five Vitamin Ds. | 2018-08-23 |
20180235983 | METHOD OF PREPARING NANOPARTICULATE TOPICAL COMPOSITION - The present invention relates to a method of preparing a nanoparticulate topical composition of a water soluble, water-susceptible active ingredient or its pharmaceutically acceptable salt, the method comprising steps of milling the water soluble, water-susceptible active ingredient or its salt, a wetting agent and a non-aqueous liquid vehicle to obtain a non-aqueous nanosuspension and converting the non-aqueous nanosuspension into a topical composition. | 2018-08-23 |
20180235984 | TETRACYCLINE MANAGEMENT OF EGFR INHIBITOR ASSOCIATED DERMATOSES - Methods of treatment and dosage regimes using a composition comprising a tetracycline antibiotic in treating or alleviating a disorder including EGFRI associated rash, EGFRI associated rash related symptoms, a tetracycline antibiotic responsive EGFRI associated rash related disorder, skin disorder caused by a bacteria, and a tetracycline antibiotic responsive sebaceous gland disease, P. EGFRI associated rash bacteria associated disorders and other superficial infections, including skin infections are provided. | 2018-08-23 |
20180235985 | COMPOSITIONS FOR ORAL ADMINISTRATION OF ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR TREATING DISEASE - Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions. | 2018-08-23 |
20180235986 | COMBINATION THERAPY FOR CANCER TREATMENT - The present disclosure relates to methods for treating cancer, or preventing cancer recurrence or progression, comprising administering a patient an anti-CD38 antibody and a proteasome inhibitor. | 2018-08-23 |
20180235987 | GLYCAN COMPOSITIONS AND USES THEREOF - Compositions comprising glycan therapeutics, optionally comprising one or more oligo- or polysaccharides, probiotics, prebiotics and other agents are provided. Further, methods of generating said glycan therapeutics using polymeric catalysts are described. Also provided are methods of using said gycan therapeutics, e.g. for the modulation of vaginal microbiota. | 2018-08-23 |
20180235988 | SIALYLATION-INCREASING THERAPIES FOR DISEASES ASSOCIATED WITH OXIDATIVE STRESS - Methods are disclosed for treating a subject with a vascular or cardiac disorder associated with oxidative stress. Methods are disclosed for treating a subject with GNE myopathy that has impaired cardiac function. These methods include administering to the subject a therapeutically effective amount of a sialic acid precursor, sialic acid, or one or more sialylated compounds, mannosamine, N-acetyl mannosamine or a derivative thereof. In other embodiments, methods are disclosed for detecting a disorder associated with oxidative stress. | 2018-08-23 |
20180235989 | TREATMENT AND PREVENTION OF NEISSERIA GONORRHOEAE INFECTION USING CMP-ACTIVATED NONULOSONATE ANALOG COMPOUNDS - There is provided a method for treating or preventing a | 2018-08-23 |
20180235990 | FLAVONOID COMPOSITIONS AND RELATED METHODS - Flavonoids that are isolated from plant material of the genus | 2018-08-23 |
20180235991 | MANNOSE DERIVATIVES USEFUL FOR TREATING PATHOLOGIES ASSOCIATED WITH ADHERENT E. COLI - The present invention relates to mannose derivatives of formula (I): | 2018-08-23 |
20180235992 | IMMUNOTHERAPIES FOR MALIGNANT, NEURODEGENERATIVE AND DEMYELINATING DISEASES BY THE USE OF TARGETED NANOCARRIERS - A method for the targeted delivery of the active generic antiproliferative and anti-inflammatory agents gemcitabine, paclitaxel and/or curcumin preferentially or exclusively to antigen-presenting cells (APCs) of the immune system by means of encapsulation into a lipid-based nanocarrier, the CLR-TargoSphere, which is surface-labeled with a Fucose-derivative ligand that exclusively targets C-type lectin receptors (CLRs) on APCs to deliver the active agents intracellularly to myeloid dendritic cells (mDCs), circulating monocytes, macrophages, and tumor-associated macrophages (TAMs) as well as cytotoxic T lymphocytes (CTLs). | 2018-08-23 |
20180235993 | METHODS AND COMPOSITIONS FOR TREATING FLAVIVIRUSES AND PESTIVIRUSES - A method and composition for treating a host infected with flavivirus or pestivirus comprising administering an effective flavivirus or pestivirus treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided. | 2018-08-23 |
20180235994 | COMPOSITIONS AND METHODS FOR TREATING VASCULAR MALFORMATION AND RELATED CONDITIONS - In one aspect, the present invention features a method of inhibiting proliferation and/or reducing survival of a cell comprising a GNAQ polynucleotide or polypeptide having a R183Q or Q209L mutation, comprising contacting the cell with puromycin or a puromycin analog, thereby inhibiting proliferation and/or reducing survival of the cell. In another aspect, a method of treating a vascular malformation or related condition in a subject, comprising administering to the subject an effective amount of puromycin or a puromycin analog is featured. In another aspect, the present invention features a method of identifying a candidate agent that modulates a GNAQ R183Q or Q209L mutation-associated disease, comprising contacting a cell comprising a GNAQ polynucleotide or polypeptide having a R183Q or Q209L mutation with puromycin and a candidate agent and comparing viability of the contacted cell with a reference level of viability, wherein an alteration in viability indicates that the candidate agent modulates the GNAQ R183Q or Q209L mutation-associated disease. | 2018-08-23 |
20180235995 | RNA INTERFERENCE THERAPEUTICS AGAINST EBOLA VIRUS - This invention provides methods and compositions for inhibiting Ebola virus and Ebola infection utilizing gene silencing siRNAs. The siRNAs can be targeted to one or more Ebola genes including NP, VP30, VP35, L polymerase, glycoprotein (GP), VP24, VP40, and intergenic overlapping regions selected from NP/VP35, VP35/VP40, GP/VP30, and VP24/L. A composition containing the siRNAs can be administered in a delivery vehicle such as liposomes. | 2018-08-23 |
20180235996 | Methods and Compositions for Treating Cancers and Enhancing Therapeutic Immunity by Selectively Reducing Immunomodulatory M2 Monocytes - The present disclosure provides pharmaceutical compositions comprising nucleic acids capable of targeting IGF-1R expression in M2 cells. The present disclosure also provides methods for the selective reduction of M2 cells by targeting expression of IGF-1R in these cells. The present disclosure further provides methods for treating cancer and enhancing therapeutic by targeting expression of IGF-1R in M2 cells in patients. The pharmaceutical composition of the present invention is effective when administered systemically to subjects in need thereof. The ease of administration of the pharmaceutical composition facilitates treatment and enhances patient compliance. | 2018-08-23 |
20180235997 | METHODS AND COMPOSITIONS FOR ADMINISTRATION OF IRON - The present invention generally relates to treatment of iron-related conditions with iron carbohydrate complexes. One aspect of the invention is a method of treatment of iron-related conditions with a single unit dosage of at least about 0.6 grams of elemental iron via an iron carbohydrate complex. The method generally employs iron carbohydrate complexes with nearly neutral pH, physiological osmolarity, and stable and non-immunogenic carbohydrate components so as to rapidly administer high single unit doses of iron intravenously to patients in need thereof. | 2018-08-23 |
20180235998 | POLYMERS AND THEIR METHODS OF USE - Described herein are methods for treating inflammation, swelling and secondary damage of the vascular and lymphatic system in a subject, for example of the brain, spinal cord, and lungs; from organ reperfusion, e.g., resulting from endothelial leakage, glycocalyx dysfunction or loss of structural integrity of the glycocalyx. | 2018-08-23 |
20180235999 | PHYSICAL MULTI-IMPACT LIQUID-STATE ENERGY WATER, MANUFACTURING METHOD THEREOF AND DEVICE APPLYING THE SAME - A manufacturing method of a physical multi-impact liquid-state energy water is provided. The manufacturing method includes processing water by a coarse filtering process, a first standing process, a fine filtering process, a second standing process, a centrifugation process, a third standing process and a spiral pressurization process. The physical multi-impact liquid-state energy water is manufactured by repeated multiple impacts, and is water in small molecular groups having micro-vibration element liquid-state energy and having a value of frequency of nuclear magnetic resonance in full width at half maximum under 100 Hz. Water molecular groups of nearby regions are activated by physical resonance to miniaturize the water molecular groups of the nearby regions, in a way that the size of the water molecular groups of the nearby regions is fundamentally changed. The present invention is applicable to various products to promote maintaining body health. | 2018-08-23 |
20180236000 | PREVENTION AND TREATMENT FOR MICROBIAL INFECTIONS - The present invention features a composition comprising zinc pyrithione and silver sulfiadizine, a formulation thereof and a method of treating microbial infection using the composition. | 2018-08-23 |
20180236001 | METHODS OF GROWING ACID RESISTANT LAYERS ON TOOTH ENAMEL - A method of reducing tooth decay may include growing one or more acid resistant layers on tooth enamel. The acid resistant layer may include a monofluorophosphate anion. For example the acid resistant layer may include calcium monofluorophosphate. An acid resistant layer may be grown by delivering a two-part compound to the tooth enamel. | 2018-08-23 |
20180236002 | COMPOSITIONS AND METHODS FOR TREATING GRAFT VERSUS HOST DISEASE - A method of preventing the development of GvHD or reducing the severity of GvHD in a mammalian subject receiving an allogeneic hematopoietic stem cell (HSC) transplant includes administering to the subject a pharmaceutical composition comprising an active agent that inhibits the biological activity or expression of hypoxia-inducible factor-1a (HIF-1a) or hypoxia-inducible factor-2a (HIF-2a), wherein the active agent is administered in an amount effective for preventing or reducing the severity GvHD in the subject. | 2018-08-23 |
20180236003 | Cell Expansion Methods and Therapeutic Compositions - The invention relates to methods for the production of mesenchymal stem cells (MSCs), in particular to methods for the large scale production of MSCs, such as allogeneic MSCs, for use in treating various diseases in humans and other animals. The invention also relates to methods which permit the selection of preferred donor cells suitable for l arge scal e production of MSCs. The invention also relates to purified MSCs prepared by the methods of the invention. The invention also relates to the use of platelet lysate in methods for preparing cultures of MSCs and to the preparation of extracellular matrix-enriched secretions. The invention also relates to methods for the preparation of compositions comprising one or more component(s) secreted from cultured MSCs, having improved stability characteristics. The invention also relates to methods for treating inflammatory conditions, including alleviating the pain thereof, by administering high molecular mass glycoconjugate-enriched conditioned media, and to methods for treating neuropathic pain by administering high molecular mass glycoconjugate-enriched conditioned media. | 2018-08-23 |
20180236004 | STEM CELL-DERIVED OLIGODENDROCYTE PROGENITOR CELLS FOR THE TREATMENT OF WHITE MATTER STROKE - In various embodiments methods and compositions for improving a recovery of a subject after a cerebral ischemic injury, such as white matter stroke are provided. In various embodiments, the methods involve administering stem cell-derived oligodendrocyte progenitor cells into or directly adjacent to the infarct core in the brain of the subject. | 2018-08-23 |
20180236005 | FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE - The present invention concerns methods and compositions for differentiating cells, including human fibroblasts, into chondrocyte-like cells via in vivo mechanical strain. In particular aspects, fibroblasts are delivered to a joint, such as an intervertebral disc, following which the fibroblasts differentiate into chondrocyte-like cells to treat dysfunction of cartilage therein, including to repair degenerated discs, for example. The fibroblasts that do not differentiate to chondrocytic cells because of the location of the cells, as in the fissures of annulus, or other biomechanical and biochemical micro-environment factors, may produce fibrous matrix molecule(s) in aiding tissue repair and regeneration in both nucleus pulposus and annulus fibrosus. In certain aspects, the fibroblasts prior to delivery to the individual are managed in the absence of growth factors, in vitro mechanical strain, and/or matrix molecules, for example. | 2018-08-23 |
20180236006 | METHODS OF PRODUCING PANCREATIC HORMONES - Disclosed herein are methods of producing pancreatic hormone-expressing cells by first differentiating pluripotent cells in cell culture so as to produce endodermal cells, the endodermal cells being competent to further differentiate into hormone-expressing cells capable of secreting at least one pancreatic hormone in response to a physiological signal, and then, transplanting the cultured endodermal cells into an organism, such as an organism in need of an endocrine cell therapy. | 2018-08-23 |
20180236007 | UMBILICAL CORD-DERIVED ADHESIVE STEM CELLS, PREPARATION METHOD THEREFOR, AND USE THEREOF - Disclosed are enhanced umbilical cord-derived adhesive stem cells, a preparation method therefor, and a use thereof. The enhanced umbilical cord-derived adhesive stem cells have an anti-inflammatory effect, a blood vessel regeneration effect, or a nerve regeneration effect, thereby being usable in a pharmaceutical composition or a cell therapeutic agent for treating or preventing various diseases. | 2018-08-23 |
20180236008 | Topical Skin Healing Salve - A topical skin healing salve and method of making the same for treating and healing a wide variety of injuries, ailments and other skin conditions. The salve of the present invention comprises beeswax, white petroleum jelly or said castor bean jelly, unprocessed honeycomb or honey, yellow dock root, yellow dock leaves, marigold and/or calendula leaves, plantain weed and chickweed. The method of the present invention melts the beeswax, petroleum or castor bean jelly and honeycomb and/or honey. The other ingredients are added to the mixture and the combination is simmered to leach out the beneficial qualities thereof. The mixture is strained and placed in containers to cool and solidify. The salve has healing, pain relieving, anti-inflammatory, antiseptic, antibacterial properties and is water resistant and resistant to being easily washed or scraped off. The petroleum or castor bean jelly softens the skin to improve active ingredient interaction with the damaged skin. | 2018-08-23 |
20180236009 | BUCKWHEAT HONEY AND BACITRACIN WOUND-HEALING DRESSING - The present invention is a method of treating acute and chronic wounds and skin conditions. The product comprises a composition or formulation comprising a mixture of buckwheat honey and bacitracin. In one unique embodiment the composition is gelled. The composition is applied directly to a wound or a patient's skin or is impregnated on gauze or other similar material on a bandage or dressing for application to an exuding or non-exuding acute or chronic wound or skin condition. | 2018-08-23 |
20180236010 | SYSTEMS AND METHODS FOR IMPROVING PRODUCTIVITY, HEALTH AND LIFE EXPECTANCY IN AQUACULTURE INDUSTRY - A system and method, to improve productivity, health and Life expectancy of aquatic animals using an efficient and cost effective natural effector composition comprised of gram negative bacilli and is available in suitable packaging for marketing in various quantity forms as per the need of end users such as aquarium fish exporters, importers, warehouses, retailers and like. The said effector composition reduces nitrates, nitrites, and ammonia level drastically in short time and close to 0% and retains them at low concentrations consistently. Further, the DAO, DAA, DA7 associated with transportation of aquatic animals can be bought down to 0%. | 2018-08-23 |
20180236011 | METHODS TO ENHANCE TUMOR-TARGETING BY BACTERIA - Methods using chemotherapy drugs promote targeting of | 2018-08-23 |
20180236012 | DYNAMICALLY-ADAPTIVE LIVE THERAPEUTIC AGENTS AND METHODS OF USE THEREOF - This disclosure provides microbes engineered to detect virulent and spore states of pathogens and release an appropriate therapeutic response accordingly and compositions and methods of use of the same. | 2018-08-23 |
20180236013 | METHODS FOR MAKING AND USING ANTIMICROBIAL PEPTIDES - Provided herein are genetically modified microbes. In one embodiment, a genetically modified microbe includes an exogenous polynucleotide that includes a pheromone-responsive region. In one embodiment, the pheromone-responsive region is derived from a conjugative plasmid from a member of the genus | 2018-08-23 |
20180236014 | BACTERIAL STRAINS BELONGING TO THE GENUS BIFIDOBACTERIUM FOR USE IN THE TREATMENT OF HYPERCHOLESTEROLAEMIA - Selected bacterial strains belonging to the genus | 2018-08-23 |
20180236015 | COMPOSITION HAVING LACTOBACILLUS PLANTARUM STRAIN GMNL-662 FOR PROMOTING BONE REGROWTH - A composition having | 2018-08-23 |
20180236016 | NEUROTRANSMITTER AND BRAIN MODULATING ORAL DELIVERY SYSTEM FOR ENHANCEMENT OF COGNITIVE FUNCTIONS AND ENERGY - Disclosed is a composition and method for making a cognitive function neuromodulation emulsified composition comprising oil soluble and water soluble cognitive function brain modulating source component, a lipid source component, a lipid emulsifier source component a carbohydrate source component, and cocoa source component. Also disclosed does a composition and method for increasing energy and mental focus utilizing a neurotransmitter modulating source component. A method for treating degenerative cognitive functions is also disclosed. | 2018-08-23 |
20180236017 | Food Grade Cannabis Extracts and Methods for Their Preparation - Food grade | 2018-08-23 |
20180236018 | HERBO-MINERAL FORMULATION FOR PREVENTION, TREATMENT AND MANAGEMENT OF DIABETES AND METHOD OF PREPARATION THEREOF - Herbo-mineral formulation for prevention, treatment and management of Diabetes and method of preparing the same are disclosed herein. The disclosed herbo-mineral formulation includes herb and mineral elements which facilitate in treating Diabetes and Diabetes associated complications. Further the disclosed formulation has been observed to exhibit hypoglycemic, hypolipidemic, and pancreatic cell regenerative properties. | 2018-08-23 |
20180236019 | ANTIMICROBIAL & ANTIVIRAL COMPOSITION - A method of reducing the number of microorganisms entering the nose and proliferating in the nasal cavity including application of a solution of an antimicrobial, antiviral and antifungal composition to the anterior vestibular region of the nares. The antimicrobial, antiviral and antifungal solution includes ethyl alcohol as an active ingredient. Various embodiments may also include one or more of the following additional ingredients: orange oil; lemon oil; grapefruit oil; tangerine oil; mandarin oil; lime oil; bergamot oil; petitgrain essential oil; and other citrus oils; meadowfoam seed oil; soy oil; emu oil; grapefruit seed extract; glycine soja; simmondsia chinensis (Jojoba); lauric acid; chlorhexidine gluconate; ginger oil; lavender oil; peppermint oil; spearmint oil; aloe oil; one or more terpenes and/or terpenoids; and a preservative, such as benzalkonium chloride and vitamin E. | 2018-08-23 |
20180236020 | BUCKWHEAT HONEY AND POVIDONE-IODINE WOUND HEALING DRESSING - The present invention is a method of treating acute and chronic wounds and skin conditions. The product comprises a composition or formulation comprising a mixture of buckwheat honey and povidone-iodine. In one unique embodiment the composition is gelled. The composition is applied directly to a wound or a patient's skin or is impregnated on gauze or other similar material on a bandage or dressing for application to an exuding or non-exuding acute or chronic wound or skin condition. | 2018-08-23 |
20180236021 | METHOD, APPARATUS AND COMPOSITIONS FOR THE PROPHYLAXIS AND TREATMENT OF COLONY COLLAPSE DISORDER - This invention concerns a method for preventing and treating Colony Collapse Disorder, consisting in the use of an automated device that delivers a diet specifically calibrated for consumption by farm colonies of bees to be treated. The apparatus comprises a box-like container ( | 2018-08-23 |
20180236022 | NOVEL BIOACTIVE COMPOUND OBTAINED FROM OIL PALM BASE MATERIALS - This disclosure is directed to a novel bioactive compound obtained from oil palm based materials and compositions containing said bioactive compound. The bioactive compound obtained in accordance with the present invention has a molecular mass of 482. The bioactive compound also has potent HIV reverse transcriptase activity and antioxidant activity. | 2018-08-23 |
20180236023 | DIETARY COMPOSITION FOR PREVENTING, REDUCING, ALLEVIATING OR TREATING IDIOPATHIC VOMITING - The present invention relates to compositions containing plant materials or extracts with inhibitory effect on a 5-HT | 2018-08-23 |
20180236024 | IRGM AND PRECISION AUTOPHAGY CONTROLS FOR ANTIMICROBIAL AND INFLAMMATORY DISEASE STATES AND METHODS OF DETECTION OF AUTOPHAGY - The present invention relates to the discovery that IRGM, encoded by a uniquely human gene which confers risk for inflammatory diseases, affects autoophagy through a hitherto unknown mechanism. The present invention shows that IRGM controls autophagy and that IRGM modulators, in particular, double-stranded RNA, including poly I:C, poly-UG (polyUGUGU) and polyl-CLC and muramyldipeptide and related analogs of same, including N-acetyl muramyl-L-alanyl-D-isoglutamine (DMP) and numerous other compounds as identified herein, which may be used alone, in combination, or in combination with alternative autophagy modulators and additional bioactive agents to provide effective therapies for a number of diseases, including cancer, bacterial infections and inflammatory diseases, especially including tuberculosis infections and Crohn's disease, among others. The present invention is also directed to compositions and methods for treating inflammatory or autophagy-related diseases including diseases which cause excessive inflammation in patients. | 2018-08-23 |
20180236025 | METHODS FOR THE PREVENTION OR TREATMENT OF HEART FAILURE - The disclosure provides methods of preventing or treating heart failure in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof. | 2018-08-23 |
20180236026 | PEPTIDE REGULATORS OF JNK FAMILY KINASES - The present disclosure relates to the fields of proliferative disorders (for example, cancer) and disorders associated with excessive cell death (for example, neurodegenerative disorders). | 2018-08-23 |
20180236027 | DOSES AND METHODS FOR ADMINISTERING TELAVANCIN - Doses and methods for administering telavancin or a pharmaceutically-acceptable salt thereof to a human patient having an infection caused by | 2018-08-23 |
20180236028 | REELIN RESCUES COGNITIVE FUNCTION - Disclosed are methods of influencing, and enhancing, cognitive function and memory by increasing, and/or preventing interference with, Reelin levels as well as Reelin signaling. Cognitive function is improved, in a subject in need thereof, by administering a therapeutically effective amount of Reelin, a Reelin-specific modulator or an agonist of a lipoprotein receptor to the subject. The lipoprotein receptor can be selected from candidates such as ApoER2 and VLDLR. As disclosed herein, agonists of the lipoprotein receptor for use with the inventive method include APC, Sep and Fc-RAP. In addition to administering exogenous Reelin, a Reelin-specific modulator, such as a recombinant Reelin fragment, can be used to increase Reelin levels and/or signaling. | 2018-08-23 |
20180236029 | ISOFORM NELL-1 PEPTIDE - This application is drawn to a method of using an isoform NELL-1 peptide, and compositions thereof for bone formation or for treating, preventing, or ameliorating osteoporosis. | 2018-08-23 |
20180236030 | STABLE PHARMACEUTICAL COMPOSITION OF TNFR:FC FUSION PROTEIN - The present invention relates to the stable pharmaceutical compositions comprising tumor necrosis factor receptor Fc fusion protein (TNFR:Fc). More particularly, it relates to the stable pharmaceutical compositions comprising tumor necrosis factor receptor Fc fusion protein (TNFR:Fc), phosphate-citrate buffer. It also relates to the methods of manufacturing the composition, method of administration and kits containing the same. | 2018-08-23 |
20180236031 | COMPOSITIONS AND METHODS FOR RECOMBINANT NERVE GROWTH FACTOR - The present application provides nerve growth factor (NGF) variants with improved in vivo stability, methods for producing and purifying NGF variants, as well as potential therapeutic applications. | 2018-08-23 |
20180236032 | COMBINATION COMPOSITION COMPRISING FGF-18 COMPOUND - The present invention relates to the use of an FGF-18 compound in combination with a further active ingredient, selected from the group of an inhibitor of IL-6, an inhibitor of IL-6 receptor, an inhibitor of NGF or a botulinum toxin compound. Said composition can be used for the treatment of a cartilage disorder such as osteoarthritis or cartilage injury. | 2018-08-23 |
20180236033 | PHARMACEUTICAL COMPOSITION FOR TREATING A METABOLIC SYNDROME - The invention is directed to a pharmaceutical composition containing at least one FGF-21 (fibroblast growth factor 21) compound, at least one GLP-1R (glucagon-like peptide-1 receptor) agonist and optionally at least one anti-diabetic drug and/or at least one DPP-4 (dipeptidyl peptidase-4) inhibitor for the treatment of at least one metabolic syndrome and/or atherosclerosis, in particular diabetes, dyslipidemia, obesity and/or adipositas. | 2018-08-23 |
20180236034 | Compositions and Methods of Using Anti-Mullerian Hormone for Treatment of Infertility - The present invention provides compositions and methods for the treatment of subjects with impaired fertility or at risk for impaired fertility. In certain aspects, the invention relates to increasing the level or activity of anti-Mullerian hormone (AMH) in a subject. | 2018-08-23 |
20180236035 | PROTEIN THERAPY FOR TREATMENT OF RETINAL DISEASES - The present invention encompasses methods, compositions, and devices for treating an ocular disease, disorder or condition in a mammal. The invention includes polypeptides that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties, and their application in the treatment of eye disease, particularly diseases of the retina. In particular aspects, the invention includes administration of a therapeutic polypeptide such as a stanniocalcin family member protein for the treatment of an eye disease. Also included are fusion proteins and cells stimulated or modified to express the therapeutic polypeptides as set forth herein. | 2018-08-23 |
20180236036 | USE OF THYMOSIN ALPHA FOR THE TREATMENT OF SEPSIS - The present invention provides methods for preventing, treating, or reducing the severity of sepsis, severe sepsis or septic shock, including bacterial, viral, and fungal infections, and including infections of more complex etiology. The invention involves the administration of an alpha thymosin peptide regimen. In certain embodiments, the alpha thymosin peptide regimen is scheduled or timed with respect to potential, expected and/or diagnosed sepsis, severe sepsis or septic shock. In certain embodiments, the patient is immunodeficient or immunecompromised, and/or the patient is hospitalized or scheduled for hospitalization, such that the regimen of alpha thymosin peptide peptide helps to protect the patient from, or reduce the severity of, sepsis, severe sepsis or septic shock. | 2018-08-23 |
20180236037 | FGF21 COMPOUND / GLP-1R AGONIST COMBINATIONS WITH OPTIMIZED ACTIVITY RATIO - The present invention relates to combinations, pharmaceutical compositions and fusion molecules comprising an FGF21 (fibroblast growth factor 21) compound and a GLP-1R (glucagon-like peptide-1 receptor) agonist with optimized GLP-1R agonist/FGF21 compound activity ratio. It further relates to their use as medicaments, in particular for the treatment of obesity, being overweight, metabolic syndrome, diabetes mellitus, diabetic retinopathy, hyperglycemia, dyslipidemia, Non-Alcoholic SteatoHepatitis (NASH) and/or atherosclerosis. | 2018-08-23 |
20180236038 | Liraglutide in cardiovascular conditions - The present invention relates to the GLP-1 receptor agonist liraglutide for use in medicine. | 2018-08-23 |
20180236039 | HIGH OSTEOCALCIN MICROCRYSTALLINE HYDROXYAPATITE FOR CALCIUM SUPPLEMENT - An improved manufacturing process produces microcrystalline hydroxyapatite with sustained gradual calcium release that avoids spiking in blood calcium levels. Although the improved material did not cause significant elevation of blood calcium, it was just as effective in promoting bone mineralization as conventional calcium supplements. In addition, the material has much higher levels of bone growth factors as compared to prior hydroxyapatite products. | 2018-08-23 |
20180236040 | USE OF A PHARMACEUTICAL COMPOSITION CONTAINING AT LEAST ONE DIGESTIVE ENZYME IN ARTIFICIAL FEEDING - The invention relates to the use of a pharmaceutical composition in combination with a tube food provided for artificial feeding in the treatment of digestive disorders in case of artificial feeding, where the pharmaceutical composition contains or consists of at least one digestive enzyme, preferably a lipase, particularly preferably a bacterial lipase, most preferably burlulipase (INN) in liquid dosage form, wherein the pharmaceutical composition and the tube food are formulated for being administered simultaneously but separately from each other. The pharmaceutical composition can therefore be administered simultaneously and continuously during the administration of the tube food, but separately from it. As a result, the digestive performance of a patient being artificially fed can be enhanced significantly. | 2018-08-23 |